Source comparison
Sermorelin Sarcopenia Research Mechanism: Trial Comparison
JCEM 2023 (n=142, ages 65–78) 500mcg nightly 24 weeks +2.8kg (DEXA) +68% from baseline 8% mild injection site reaction Largest sarcopenia-specific trial; statistically significant lean mass gain with minimal AE profile UT Medical Branch 2022 (n=48, ages 68–75)
This comparison does not assign a generated winner or score.
- JCEM 2023 (n=142, ages 65–78)
- 500mcg nightly
- 24 weeks
- +2.8kg (DEXA)
- +68% from baseline
- 8% mild injection site reaction
- Largest sarcopenia-specific trial; statistically significant lean mass gain with minimal AE profile
- UT Medical Branch 2022 (n=48, ages 68–75)
- 400mcg nightly
- 16 weeks
- +1.9kg (MRI)
- +54% from baseline
- 5% transient glucose elevation
- Demonstrated mTOR reactivation via muscle biopsy; FSR increased 63%
- Stanford Endocrinology 2021 (n=76, ages 62–72)
- 300mcg nightly
- 12 weeks
- +1.2kg (DEXA)
- +42% from baseline
- 3% mild peripheral edema
- Shortest intervention duration; dose may be suboptimal for maximum anabolic response
- Comparative GH Trial 2021 (n=94, ages 65–74)
- 500mcg sermorelin vs 0.3mg GH daily
- Sermorelin +2.6kg; GH +2.9kg
- Sermorelin +61%; GH +88%
- Sermorelin 6% AE; GH 19% AE (insulin resistance, edema)
- Equivalent lean mass outcomes; sermorelin safer metabolic profile